发明名称 Soluble endoglin and uses thereof
摘要 The invention provides isolated soluble endoglin polypeptides, nucleic acids encoding soluble endoglin polypeptides, antibodies that specifically bind soluble endoglin polypeptides, and kits containing these materials. The invention also provides methods for treating or decreasing the likelihood of developing a soluble endoglin-mediated disorder in a subject requiring the administration of an agent capable of reducing the expression or biological activity of a soluble endoglin polypeptide and methods for treating or decreasing the likelihood of developing a soluble endoglin-preventive disorder in a subject requiring the administration of a soluble endoglin polypeptide or a nucleic acid encoding the soluble endoglin polypeptide. The invention further provides methods for the diagnosis of a soluble endoglin-mediated disorder or a soluble endoglin-preventive disorder and methods for identifying a compound to treat a soluble endoglin-mediated or a soluble endoglin-preventive disorder.
申请公布号 US9562233(B2) 申请公布日期 2017.02.07
申请号 US201414306393 申请日期 2014.06.17
申请人 Beth Israel Deaconess Medical Center, Inc. 发明人 Topors Mourad
分类号 C12N15/113;C07K16/28;C07K14/705;A61K38/00 主分类号 C12N15/113
代理机构 Clark & Elbing LLP 代理人 Bieker-Brady Kristina;Clark & Elbing LLP
主权项 1. An isolated inhibitory nucleic acid molecule, wherein said inhibitory nucleic acid molecule comprises at least one strand comprising a nucleic acid sequence complementary to a nucleic acid sequence that encodes an amino acid sequence that is at least 85% identical over the entire sequence of VRWTVTC (SEQ ID NO: 2), and wherein the inhibitory nucleic acid molecule reduces or inhibits the expression or a biological activity of a soluble endoglin.
地址 Boston MA US